ctDNA test to help decide on radiation after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study uses a blood test (ctDNA) to help doctors decide if you need radiation after lung cancer surgery. The goal is to personalize your treatment and avoid unnecessary radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have stage 2 or 3 non-small cell lung cancer (NSCLC) and have had surgery to remove the tumor.
- You are in generally good health (able to care for yourself and do light activities).
- You cannot have another active cancer or a history of certain lung conditions like pneumonitis or interstitial lung disease.
- You have not stopped cancer treatment earlier because of severe side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.